CPD Courses
The Investigational New Drug Application (IND) to Conduct FDA-regulated Clinical Trials
Online Course • grapl
About the CPD course
An Investigational New Drug Application (IND) is a submission to the US Food and Drug Administration (FDA) for permission to conduct a clinical trial of a medicinal product. This module describes regulatory requirements that sponsors or sponsor-investigators must meet for successful compilation; filing and maintenance of INDs. The IND and its role are defined; and the contexts in which it is required are specified. The information that must be included and the format in which it needs to be presented are outlined. The process of review by the FDA is described; and the outcomes and sponsor’s responses are discussed.
Send an enquiry
grapl
grapl is a UK based digital learning and development specialist, authoring and designing Zenosis® courses to provide an extensive eLearning library for the pharmaceutical, biotech and medicinal products sector. This learning can be delivered via the customers LMS, the grapl LMS or its social, knowledge and collaborative CloudRooms platform. Continuously updated to reflect regulatory changes, Zenosis® courses are trusted to educate their people by some of the worlds leading companies.
Want to learn more?
More CPD courses by grapl
Education
An Introduction to Drug Safety and Pharmacovigilan...
grapl
Drug safety monitoring and risk management are vitally important for medicinal product developers; l...
Online Course
Education
An Introduction to Clinical Trials and Drug Develo...
grapl
This course provides an understanding of how clinical trials fit into the drug development process....
Online Course
Education
An Introduction to Clinical Trial Preparation and...
grapl
Worldwide expenditure on R&D by the pharmaceutical industry is continually increasing. Most of the f...
Online Course
Education
ICH Good Clinical Practice
grapl
Good Clinical Practice (GCP) is a set of internationally recognised ethical and scientific quality r...
Online Course
Get industry-related content straight to your inbox
Thank you for subscribing
By signing up to our site you are agreeing to our privacy policy